MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Operating Income 2011-2026 | CVAC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -412 M | -110 M | -99.5 M | -72.8 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -72.8 M | -412 M | -174 M |
Quarterly Operating Income CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -15.3 M | - | - | - | -116 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -15.3 M | -116 M | -65.6 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.68 | 2.44 % | $ 429 M |  Britain |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Kamada Ltd.
KMDA
|
-696 K | $ 8.81 | 1.73 % | $ 260 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Adagene
ADAG
|
-36 M | $ 3.26 | 0.62 % | $ 183 M |  China |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.81 | -9.28 % | $ 27.9 M | Israel |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-12.5 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-1.03 M | $ 0.88 | -1.43 % | $ 442 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 224.42 | -2.52 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 4.13 | 0.12 % | $ 352 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.36 | 2.27 % | $ 14.8 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
-30 M | - | 17.91 % | $ 11.1 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Codexis
CDXS
|
-58.5 M | $ 1.17 | -0.85 % | $ 85.9 M | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 110.12 | -0.28 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
249 M | $ 14.49 | -0.75 % | $ 4.48 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |